News

October 2, 2023

Expands Clade’s pipeline and broadens its platform with:– proprietary gamma/delta (g/d) TCR universal targeting platform technology,– g/d TCR candidate integrated into Clade’s solid tumor pipeline BOSTON, Mass. – October 2, 2023 – Clade Therapeutics (“Clade”), a biopharmaceutical company focused on discovering and delivering engineerable, off-the-shelf, scalable, and consistent stem cell-based medicines, today announced that it […]

March 10, 2022

Dr. Hei has spent over two decades leading manufacturing teams at biotechnology companies and has deep expertise in the cell therapy space CAMBRIDGE, Mass. – March 10, 2022 – Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based medicines, today announced the appointment of Derek Hei, Ph.D., as its […]

November 3, 2021

Clade’s iPSC immune cloaking and differentiation platform technology to address compatibility, durability, reproducibility and scalability of cell therapies CAMBRIDGE, Mass. – November 3, 2021 – Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based medicines, today announced it has secured an $87 million Series A financing led by Syncona […]